TSTickerStarGet alerts
Company alerts/VBIO
VBIO company alerts

VBIO updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for VBIO. Subscribe to VBIO alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for VBIO alertsView companies
Official-source feed

Recent VBIO alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Company updateOfficial company source

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks

Valion Bio received unsolicited acquisition inquiries from independent third parties concerning its wholly owned CDMO subsidiary, Velocity Bioworks, and is in preliminary discussions while evaluating strategic options. A potential sale could provide additional capital for Entolimod's ongoing development and other corporate priorities, while retaining production rights and continued manufacturing capabilities is a key priority. Valion has not committed to a sale or any other specific transaction and said discussi...

Read source-backed brief
Company updateOfficial company source

Valion Bio Evaluates Strategic Options for Velocity Bioworks After Unsolicited Acquisition Interest

Valion Bio disclosed unsolicited acquisition inquiries from independent third parties concerning wholly owned CDMO Velocity Bioworks and said it has entered preliminary discussions while evaluating strategic options. The company has not committed to a sale or any other specific transaction and said the discussions may not lead to a definitive agreement or completed transaction. Management and the Board will consider valuation, terms, execution certainty, and potential net proceeds, with retaining Entolimod produ...

Read source-backed brief
Company updateOfficial company source

Valion Bio's Interim CEO Dean Zikria Outlines 30-Day Agenda: Entolimod Pipeline, Velocity Bioworks Commercialization, and Strategic Review

Valion Bio announced that Dean Zikria, a board director of more than seven years, has become Interim CEO and set a 30-day agenda built on three priorities: advancing Entolimod and other pipeline assets, pursuing customer and revenue growth for wholly owned CDMO subsidiary Velocity Bioworks, and evaluating strategic alternatives for Velocity including partnerships, co-investment structures, licensing deals, joint ventures, or a sale. The company disclosed that Entolimod, the lead biologic candidate for Acute Radi...

Read source-backed brief
Debt offeringSEC filing

Valion Bio enters Third Side Letter with 3i, LP for $50,000 Series B Preferred closing

On October 7, 2026, Valion Bio, Inc. and 3i, LP entered into a Third Side Letter under the existing Series B Preferred Purchase Agreement, pursuant to which 3i agreed to purchase 50 Series B Non-Voting Convertible Preferred Shares and Series B Warrants to purchase 1,539 shares of Common Stock at an initial exercise price of $2.5520 per share for an aggregate purchase price of $50,000. The securities are being issued in a private placement in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506(b). C...

Read source-backed brief